
What Is The State Of Manufacturing & Supply Chain In 2025?
This month, I'm excited to share the results of Fictiv's 10th Annual State of Manufacturing & Supply Chain Report. Every year, we survey hundreds of supply chain and manufacturing leaders across multiple industries to understand their perspectives, challenges, and predictions for 2025. I'm especially excited to dive into the broader supply chain results, particularly in a year marked by massive tariff and trade disruptions.
Our first findings concern business uncertainty. With the shift in the U.S. President's trade policies, almost 100% say they're concerned that trade wars are likely to escalate in the next few years (clearly demonstrated by widespread global tariffs).
Key Findings
96% of manufacturing leaders report they're concerned about the impact of the U.S. President's trade policies.
93% believe trade wars will likely escalate in the next few years, whereas 42% are now 'very concerned' —a 6-point increase over 2024.
91% note that global tensions are being considered in their company's long-term supply chain strategy—a 5-point increase over 2024.
Growing global business uncertainty
Looking at this chart, it's clear senior leaders are concerned about tariffs, particularly the impacts on costs and profitability, as well as global business. As a result, many are planning to increase manufacturing in the U.S.
The next key finding is around accelerating supply chain disruptions. Across the board, executives are saying they need to accelerate how they manage their supply chain. Two-thirds or 68% said that onshoring is a key priority this year for their teams.
Key Findings
68% of leaders prioritize onshoring as a key supply chain strategy in 2025, especially in industries needing complex parts at scale, like MedTech, clean energy, and EVs.
77% report a lack of resources (e.g., workforce, budget) severely limits their ability to manage their supply chains effectively (an increase over 2024).
52% of manufacturing leaders identify supplier quality, reliability, and compliance as significant challenges.
Accelerating supply chain disruptions
On the flip side, three-quarters, or 77%, say they lack the resources to effectively manage their supply chain as it is today. This is difficult given that leaders also say they want to onshore their supply chain. If supply chain resources are already limited, moving back to the U.S. will be a challenge.
50% are also saying that quality and reliability are significant challenges. Some are running well-performing supply chains, while another half are running inadequate supply chains.
Our third major finding is around scaling production. In my opinion, this has been the most difficult it's ever been. What you see here is 91% say they're facing barriers to innovation. In other words, they're struggling to find high-quality supply chain partners to do low-volume builds.
Key Findings
91% of manufacturing and supply chain leaders face barriers to product innovation and introduction, with nearly half struggling to source fast, high-quality solutions for low-volume builds.
86% report sourcing parts and materials takes time away from initiatives like new product innovation and introduction, making it increasingly difficult to move into and scale production.
90% of leaders consistently report that digital manufacturing platforms are an essential service for production (up from 86% in 2024).
Scaling production more difficult than ever
Secondly, almost 90% are saying that all the work required to source parts is taking away from innovation. In other words, you're launching a new product, and sourcing has become the bottleneck, the long pole on the tent. This makes driving innovation to build electric vehicles, rockets, and surgical equipment incredibly difficult—stalling the innovations of tomorrow.
In the 10 years we've been doing this report, we've consistently seen this trend. Executives are looking to digitize supply chains. This continues to be a key focus area and it's even up from the 86% that we saw last year. So my takeaway is that for teams that are scaling new products, and moving into production, you have to think about this as another phase of development. You have development that happens by building prototype one. Getting it in the market is the next and most difficult step.
Key Findings
95% report weather and extreme climate events are impacting their supply chain strategy in 2025.
91% now have sustainability initiatives and governance in place to help drive sustainability goals.
52% believe nearshoring and onshoring strategies are critical to supporting sustainability efforts.
Sustainability takes hold
The fourth finding centers around sustainability. This continues to be a major focus for our audience. As we know at the macro level, we've seen massive fires in California, floods and tsunamis globally, and hurricanes. These weather and extreme climate events are impacting supply chains around the world, and no industry is protected.
It's heartening to see that 91% now have sustainability initiatives and some type of governance in place, an increase from previous years. ESG has been a clear focus area for many executives and supply chain teams. However, this year, with 91% saying they have actual governance in place to do a triple bottom line, that's really encouraging to me. We're seeing sustainability as a large driver and metric for consideration in supply chains.
And lastly, nearshoring and onshoring are critical to supporting sustainability efforts. So nearshoring might not necessarily be a pure climate or sustainability play. There are other factors like economics, and geopolitical factors in play here. We thought this was an interesting takeaway. It's not just about reducing the carbon emissions by being closer to your customer, there are multiple considerations when nearshoring but excited to see this continue to be top of mind in our 10th Annual State of Manufacturing and Supply Chain Report.
And you can't have a report on the state of manufacturing in 2025 without AI. AI is the top trend shaping their long-term strategy, whether it's the latest, greatest LLMs or looking at augmenting human tasks, AI is at the forefront of our customers' minds.
Key Findings
87% of leaders report advanced levels of maturity with their company's AI implementations.
94% use AI for manufacturing and supply chain operations, such as inventory management and product design.
56% of Manufacturing and supply chain leaders identify AI as the leading trend shaping their long-term strategy, with economic headwinds following at 53%.
AI advances
Also, 87% report advanced levels of maturity in implementing AI. Almost 100% say their teams are getting better at using it for day-to-day tasks. I personally use it every single day, and I encourage all of our employees, partners, and customers to look at the ways that AI can help bring efficiencies to their work.
94% are saying that AI for manufacturing and supply chain operations is their main implementation, whether it's inventory management, product design, research, or supplier development. One of the best implementations that I saw was all around SCARS, so Corrective Action Reports and using it to help automate the process of managing supply chains. There are a lot of great applications and agentic products out there, and I would really encourage you to look at this to streamline your operations. If you don't do it, your competition will.
I think that while AI is here and will cause a lot of disruption, I think there are multiple factors to consider. So make sure you're figuring out how to implement it, implement it well, and use it daily, but it's not necessarily the silver bullet to solve all supply chain challenges.
Here are a few useful takeaways from the report for your consideration:
To download the full report, please go here. You can also watch an in-depth webinar discussion with Fictiv's General Managers of China, India, Mexico, and the U.S.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
Edwards loses longtime TAVR leader Larry Wood
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. By the numbers Q2 sales: $1.53 billion 11.9% increase year over year TAVR sales: $1.1 billion 8.9% increase year over year TMTT sales: $134.5 million 61.9% increase year over year Edwards Lifesciences boosted full-year sales and earnings estimates on growth in transcatheter aortic valve replacement and said Larry Wood, longtime leader of the TAVR business, will leave the company. Wood, Edwards' corporate vice president of TAVR since 2007, will join Procept BioRobotics as CEO on Sept. 2, Procept announced. Dan Lippis, a 15-year Edwards veteran currently overseeing the Japan, Greater China and Asia Pacific region, will replace Wood as head of TAVR, CEO Bernard Zovighian said Thursday on an earnings call. Wood helped transform Edwards' TAVR business into a multibillion-dollar franchise and will be hard to replace, but the company's well-known technologies, compendium of clinical data and robust commercial organization help allay concerns, Stifel analyst Rick Wise wrote to clients. Edwards reported a nearly 12% sales increase in the second quarter, driven by TAVR sales that beat the company's expectations and continued adoption of repair and replacement devices to treat mitral and tricuspid valve diseases. Zovighian attributed the accelerated TAVR sales to clinicians' focus on data from the company's Early TAVR study, released in October, that showed patients with severe aortic stenosis with no symptoms had better outcomes after a TAVR procedure than if managed through clinical surveillance. The company received an expanded U.S. label indication in May for use of the Sapien 3 TAVR platform in asymptomatic patients and has also gained approval in Europe for the patient population, becoming the first valve maker in both markets to offer the treatment for people without symptoms. Boston Scientific's decision in May to exit the TAVR market in Europe resulted in a 'modest' contribution to Edwards' sales in the quarter, the company said. The renewed strength in TAVR, following a slowdown last year tied to heart team capacity challenges at hospitals, prompted Edwards to raise its full-year sales growth forecast to 9%-10% from 8%-10% and TAVR sales outlook to 6%-7% from 5%-7%. The company now expects adjusted earnings per share to be at the high end of a range of $2.40 to $2.50. Mizuho Americas analyst Anthony Petrone, in a note following the earnings update, called the TAVR opportunity in severe asymptomatic cases 'expansive' ahead of a potential Medicare national coverage decision and treatment guideline shifts that could come in the next year or so. 'The evolution of policy and guideline changes together with the potential of a new U.S. NCD will provide important catalysts, resulting in a multiyear growth opportunity for TAVR overall,' Zovighian said on the call. In Edwards' smaller but fast-growing mitral and tricuspid business, the CEO said both the Evoque tricuspid valve replacement and Pascal valve repair devices were significant contributors to growth as sales continue to scale up. Zovighian said U.S. approval of the Sapien M3 transcatheter mitral valve replacement system is expected in the first half of 2026. Pivotal trial results are expected to be presented at the Transcatheter Cardiovascular Therapeutics conference later this year. Edwards gained Europe's CE mark for Sapien M3 in April. Recommended Reading Edwards gains expanded TAVR label for asymptomatic patients Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Yahoo
NJ Rallies Investment Power, Leveraging Capital from Garden State Venture Partners to Drive MedTech and Maternal Health Innovation
GLASSBORO, N.J., July 25, 2025--(BUSINESS WIRE)--Two transformative healthcare announcements this week mark a new era for New Jersey's innovation economy—with Garden State Venture Partners (GSVP) emerging as a key catalyst behind both. 1. MedTech Strategic Innovation Centers Backed by GSVP & NJEDA On July 21, NJEDA and Rowan University unveiled a major initiative to launch a Strategic Innovation Center, with locations in Camden and Mullica Hill, supporting early-stage medical technology companies with critical lab space, mentorship, and commercialization resources. GSVP, a New Jersey-based venture firm committed to fueling statewide innovation, is helping to make this possible through venture capital funding for early-stage medtech companies. Read release 2. A First-of-Its-Kind Maternal and Infant Health Innovation Center in Trenton Just one day later, Governor Murphy and First Lady Tammy Murphy broke ground on a Trenton-based center dedicated to maternal and infant health equity. The MedTech Strategic Innovation Center will also have a presence at the Maternal and Infant Health Innovation Center, which will focus on medical technologies that address racial disparities in care. Once again, GSVP will play a central role in helping bridge the gap between public health needs and private-sector innovation by accelerating promising, equity-driven health tech ventures. Read release Together, these initiatives represent over $100 million in coordinated investment, a model of public-private partnership, and a strategic bet on New Jersey as the next national hub for health tech and equity-focused innovation. GSVP's leadership and capital are essential to making that vision real. About Garden State Venture Partners Garden State Venture Partners (GSVP) is a next-gen venture capital firm built to attract and retain companies and talent within the state of New Jersey. GSVP is uniquely positioned to deepen existing partnerships and forge new ones across the state—catalyzing innovation and driving sustained economic success by connecting and investing in the state's innovation ecosystem. Learn more about GSVP at and access full leadership team bios here. View source version on Contacts Media Contact:Colleen Kendrick, CEONonprofit Partnersckendrick@ 1-800-298-9812 ext. 1
Yahoo
5 days ago
- Yahoo
Vizient Reserve Program Expands Supply Assurance to Include IV Fluids in Collaboration With Baxter
IRVING, Texas, July 23, 2025--(BUSINESS WIRE)--Vizient® announced today the expansion of the Vizient Reserve Program to include IV fluids through a strategic partnership with Baxter, a leading global medtech company, to help ensure reliable access to these critical products during times of supply disruption. The program provides participating healthcare organizations with dedicated, on-demand manufacturer inventory, warehoused in the U.S., along with comprehensive support to help safeguard continuity of care. The expansion of Vizient Reserve to include IV fluids reflects a strategic collaboration with Baxter to improve supply assurance within the healthcare supply chain and comes less than a year after Hurricane Helene hit the east coast, temporarily disrupting supply of this critical product. IV fluids—a uniquely complex category due to their essential nature, high utilization, and complex manufacturing requirements—are foundational to patient care. While Baxter's U.S. IV fluids production levels have been restored since the hurricane, the partnership between Vizient and Baxter reflects a deliberate, long-term strategy to promote resiliency and help healthcare providers prepare for and manage the pressures that natural disasters and increased demand have put on the supply of this critical healthcare category. "IV fluids are among the most relied upon therapies in healthcare. We've created a scalable, cost-effective reserve model that enhances resiliency and transparency across the supply chain," said Dan Kistner, senior vice president and general manager, category management & strategic programs, Vizient. "This approach builds on the success of our NES Reserve program in the pharmaceutical space, further demonstrating how Vizient is rethinking traditional sourcing strategies with proactive, purpose-built solutions designed to mitigate supply disruptions and ensure continuity of care." With comprehensive inventory management, transparent reporting and dedicated logistics, the program offers a flexible structure to enable access during supply disruptions and support continuity of care. "At Baxter, we are actively committed to supporting hospitals and health systems navigate any threat to supply continuity," said Cecilia Soriano, global president of Baxter's infusion therapies and technologies business. "Baxter and Vizient's shared commitment to enabling access to life-sustaining therapies is at the heart of this initiative, and we're honored to support Vizient clients in their efforts to build greater supply resilience." The new program builds on the success of Vizient Novaplus Enhanced Supply (NES) Reserve, which provides up to six months of additional dedicated manufacturer inventory for essential medications, and expands the breadth of products available through it—including the first-ever medical-surgery product codes. Since its inception, NES Reserve has fulfilled more than 45,000 requests from over 1,700 facilities, totaling more than 5 million additional units of essential medications. Learn more about IV fluids in the Vizient Reserve Program. About Vizient, Inc. Vizient, Inc., the nation's largest provider-driven healthcare performance improvement company, serves more than 65% of the nation's acute care providers, including 97% of the nation's academic medical centers, and more than 35% of the non-acute market. The Vizient contract portfolio represents $140 billion in annual purchasing volume enabling the delivery of cost-effective, high-value care. With its acquisition of Kaufman Hall in 2024, Vizient expanded its advisory services to help providers achieve financial, strategic, clinical and operational excellence. Headquartered in Irving, Texas, Vizient has offices throughout the United States. Learn more at View source version on Contacts Media ContactNancy Matocha(972)